HAG
TGTX icon

HighPoint Advisor Group’s TG Therapeutics TGTX Stock Holding History

HighPoint Advisor Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,400
Closed -$43K – 300
2016
Q3 		$43K Buy
+7,400
New +$47.6K 0.02% 276

Other funds holding TGTX

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

HighPoint Advisor Group's TGTX Position: Q4 2016 in Review

HighPoint Advisor Group sold out of TG Therapeutics (TGTX) in Q4 2016, closing a stake of 7,400 shares — an estimated $43K sold.

HighPoint Advisor Group first reported a position in TGTX in Q3 2016 and held it in 1 quarter. The position peaked at $43K in Q3 2016. 91 funds tracked by Wall St. Rank hold TGTX as of Q4 2016.

  • HighPoint Advisor Group reported no remaining TG Therapeutics position as of Q4 2016 after selling out during the quarter.
  • HighPoint Advisor Group sold 7,400 TG Therapeutics shares in Q4 2016, an estimated $43K.
  • HighPoint Advisor Group first reported a position in TG Therapeutics in Q3 2016 and held it in 1 quarter.
  • HighPoint Advisor Group's TG Therapeutics position peaked at $43K in Q3 2016.
  • 91 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2016.

Based on HighPoint Advisor Group's 13F filing for Q4 2016, filed 2 Mar 2017.